Biotricity, Inc. (BTCY)
OTCMKTS
· Delayed Price · Currency is USD
0.4168
-0.0002 (-0.05%)
Mar 28, 2025, 4:00 PM EST
Biotricity Revenue
Biotricity had revenue of $3.62M in the quarter ending December 31, 2024, with 21.73% growth. This brings the company's revenue in the last twelve months to $13.27M, up 14.09% year-over-year. In the fiscal year ending March 31, 2024, Biotricity had annual revenue of $12.06M with 25.15% growth.
Revenue (ttm)
13.27M
Revenue Growth
+14.09%
P/S Ratio
0.54
Revenue / Employee
241.20K
Employees
55
Market Cap
10.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 12.06M | 2.42M | 25.15% |
| Mar 31, 2023 | 9.64M | 1.99M | 26.00% |
| Mar 31, 2022 | 7.65M | 4.27M | 126.02% |
| Mar 31, 2021 | 3.38M | 1.97M | 138.75% |
| Mar 31, 2020 | 1.42M | 1.02M | 256.03% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| SS Innovations International | 16.04M |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| American Oncology Network | 1.76B |
Biotricity News
- 19 days ago - Biotricity expands intellectual property portfolio with 14 new patents - Seeking Alpha
- 19 days ago - Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management - GlobeNewsWire
- 5 weeks ago - Biotricity GAAP EPS of -$0.05, revenue of $3.6M - Seeking Alpha
- 5 weeks ago - Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025 - GlobeNewsWire
- 6 weeks ago - Biotricity expects to post Q3 revenue growth of 22%, cashflow breakeven - Seeking Alpha
- 6 weeks ago - Biotricity Announces Cashflow Breakeven with Biggest Quarter in History and a Revenue Increase of 11% - GlobeNewsWire
- 6 weeks ago - BTCY:CA - Earn Yield On Your Digital Gold - Seeking Alpha
- 2 months ago - Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform - PRNewsWire